---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007858"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:33:36.051615+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors

## Summary
- First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.
- Trial is safety, feasibility, dose-finding for Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
- Two-month run-in on anti-PD-1 therapy; if no tumor improvement, patient treated with Hemopurifier.
- Trial targets 9-18 patients; primary endpoint is adverse events and safety lab changes.
- Exploratory endpoints measure extracellular vesicle reduction and T cell activity improvement.

## SEC filing metadata
- accession: 0001683168-24-007858
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/0001683168-24-007858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007858
- JSON: https://secwatch.observer/filing/0001683168-24-007858.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.